Prot #CNTO1959PSO3002: A Phase 3, Multicenter, Randomized, Double-blind Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis with Random